pharma · Dyslipidemia at High to Very High Cardiovascular Risk · Suspected or confirmed Gram negative infections
Menarini Asia-Pacific
A.Menarini Australia Pty Limited
A.Menarini Australia Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dyslipidemia at High to Very High Cardiovascular Risk, Suspected or confirmed Gram negative infection
Company details
- Status
- Public
- HQ
- Singapore, SG
- Employees
- 720
- Programs
- 2
- Drugs
- 15
- Patents
- 0
Vaborem 1 g/1 g powder for concentrate for solution for infusion
Phase 2 · small molecule · Suspected or confirmed Gram negative infections
Vaborem 1 g/1 g powder for concentrate for solution for infusion for Suspected or confirmed Gram negative infections is a Phase 2 program (small_molecule) at A.Menarini Australia Pty Limited with 1 ClinicalTrials.gov record(s).
Internal code VABOR-KIDS-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- A.Menarini Australia Pty Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Suspected or confirmed Gram negative infections
- Status
- active
- Trials
- 1